Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial

Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott J. Antonia, Leora Horn, Hervé Lena, Elisa Minenza, Bertrand Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin P. Levy, Suresh G. Nair, Gérard Zalcman, Jürgen Wolf, Pierre Jean Souquet, Editta Baldini, Federico CappuzzoChristos Chouaid, Afshin Dowlati, Rachel Sanborn, Ariel Lopez-Chavez, Christian Grohe, Rudolf M. Huber, Christopher T. Harbison, Christine Baudelet, Brian J. Lestini, Suresh S. Ramalingam

Research output: Contribution to journalArticlepeer-review

997 Scopus citations

Fingerprint

Dive into the research topics of 'Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial'. Together they form a unique fingerprint.

Medicine & Life Sciences